Since genome instability can elicit cytoplasmic nucleic acid sensor pathways and innate immune responses (Mackenzie et al., 2017), the induction of cancer cell selective nuclear aberrations by WRN inactivation could provide a synergistic combination option with the approved immunotherapy agents for the benefit of MSI-H cancer patients. The gene discussed is WRN; the disease is cancer.